Iricryn

Bimatoprost, the active ingredient in Iricryn, is a prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. Its proven pharmacologic profile contributes to consistent pressure control. It is indicated for the reduction of intra‑ocular pressure in adults with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Iricryn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, and research institutions, adhering to stringent quality standards.

Bimatoprost, a prostaglandin analog, is used to lower intra‑ocular pressure in glaucoma‑related conditions.

Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Pseudoexfoliative glaucoma: helps lower pressure in this secondary open‑angle form.

Bimatoprost may cause ocular and peri‑ocular reactions.

Common Side Effects: - Conjunctival hyperemia: redness of the eye. - Increased eyelash growth: longer, thicker lashes. - Eye irritation or itching: mild discomfort. - Dry eye sensation: reduced tear film stability. - Blurred vision: transient visual disturbance. - Periorbital skin darkening: mild pigmentation.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Macular edema: swelling of the central retina. - Irregular iris pigmentation: permanent color change. - Periorbital fat atrophy: loss of orbital fat tissue. - Severe allergic reaction: swelling, rash, or anaphylaxis. - Vision loss: rapid decrease in visual acuity.

Before prescribing Bimatoprost, clinicians should evaluate ocular health and patient history.

Monitor IOP: measure intra‑ocular pressure regularly after initiation. Assess for ocular inflammation: avoid use in active uveitis. Avoid in patients with known hypersensitivity to bimatoprost or any component. Caution in corneal endothelial dysfunction: may exacerbate corneal edema. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in original container, protect from light and moisture.

Bimatoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogs: additive IOP lowering may cause hypotony. - Use with ocular NSAIDs: increased risk of ocular inflammation.

Moderate Interactions (Monitor Closely): - Concurrent topical corticosteroids: may reduce Bimatoprost efficacy. - Combination with other IOP‑lowering agents: may require dose adjustment. - Systemic carbonic anhydrase inhibitors: potential additive pressure‑lowering effect.